Ceapro Supplies Organization Update on Progress of Ongoing Progress Courses, Technological know-how and Cosmeceutical Base Enterprise

Ceapro Inc.

EDMONTON, Alberta, Feb. 23, 2024 (Globe NEWSWIRE) — Ceapro Inc. (TSX-V: CZO OTCQX: CRPOF) (“Ceapro” or the “Company”), now supplied an update on its progress across its present-day enterprise.

On December 14, 2023, the Enterprise declared it entered into a definitive arrangement to blend functions with Aeterna Zentaris Inc. (“Aeterna Zentaris”), a TSX and Nasdaq mentioned specialty biopharmaceutical organization, in an all-stock merger of equals transaction to be effected by way of a program of arrangement underneath the Canada Small business Organizations Act (the “Arrangement”). The Arrangement is subject to numerous ailments, which include the approval of the Company’s shareholders and optionholders (collectively, the “Securityholders”) at the unique conference of Securityholders scheduled for March 12, 2024 (the “Conference”). In addition to the proposed Arrangement, the Enterprise carries on to execute on development across its ongoing enhancement tasks, as comprehensive down below.

“We proceed to make promising development across all parts of our company. Supplied the current developments, we anticipate that all critical achievements things will align to develop our business design. By way of the planned merger with Aeterna Zentaris, we aim to grow to be a put together business with large prospective for benefit generation in the biopharmaceutical industry. We look forward to an thrilling foreseeable future in advance for the Corporation and producing value in the limited and long expression for all stakeholders,” stated Gilles Gagnon, M.Sc., MBA, President and CEO.

Pipeline Improvement

Ceapro’s target is on avenanthramides, beta glucan from oat and yeast and new chemical complexes/shipping programs.

  • Avenanthramides (Avs):

    • Period 1-2a medical demo remaining carried out at the Montreal Well being Institute: Next the prosperous completion of bioassays for measurement of Avs in human tissues, the trial is preserving swift development forward. Considering that December 9, 2023, three cohorts of eight balanced subjects have by now been accomplished with ascending doses from 30mg to 60mg and 120mg. No considerable adverse events have happened with the initial two doses and users of the Knowledge Security Monitoring Board will complete the full analysis of results from the 120mg cohort during the to start with week of March, currently being able to declare whether or not the demo may possibly be pursued as planned and to give a green gentle for the subsequent dosage of 240mg. These benefits are quite promising provided that the higher the dose with out basic safety considerations, the much larger the opportunity for extending to many swelling-primarily based health conditions.

  • Yeast beta glucan (YBG):

    • Specifications have been standardized and the product is prepared to be utilized for the PGX scale up assignments in Edmonton and Austria. Based on the prosperous scale up of PGX technologies and acceptance from well being authorities, this product could be supplied as an immune booster in advance of 12 months stop 2024.

New Product Enhancement

  • Whey Proteins:

    • Using its PGX Engineering, Ceapro and University of Alberta researchers correctly processed in just one inexpensive stage a quite intricate mixture containing animal-dependent proteins, and in certain whey proteins that are commonly found in liquid that stays soon after cheese production. Even though these proteins are widely applied in sport beverages, baked goods, food replacements, protein health supplements and infant formulation owing to their acknowledged nutritional and purposeful attributes, recent business purification processes have to have a lot of measures and significant amounts of drinking water. PGX Technological know-how can be a very productive and cost-effective alternate for this products presenting.

    • Success from this ground-breaking research have been printed in the Journal of Food stuff Engineering in an report titled Single-action concentration of whey proteins applying the pressurized gasoline eXpanded (PGX) liquid technological innovation: Result on physicochemical properties and scale-up,”. They have also been submitted for a presentation at the 20th European assembly on supercritical fluids in Maribor, Slovenia, Might 26-29, 2024.

Technological innovation

Cosmeceutical Foundation Company

  • From a small business point of view, though 2023 was a tough 12 months due to a reorganization from one main shopper in United states of america, we are pleased to announce that this consumer has resumed ordering from Ceapro in the course of Q1, 2024 with a +20metric ton order of avenanthramides.

To remain up to date with the Company’s development, pay a visit to Ceapro’s web site at www.ceapro.com and join on Facebook, X, and LinkedIn.

About Ceapro Inc. 

Ceapro Inc. is a Canadian biotechnology enterprise associated in the progress of proprietary extraction technological innovation and the software of this technological know-how to the generation of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further benefit to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics merchandise for human beings and animals. The Corporation has a wide array of abilities in purely natural merchandise chemistry, microbiology, biochemistry, immunology and course of action engineering. These techniques merge in the fields of active components, biopharmaceuticals and drug-shipping remedies. For extra info on Ceapro, please pay a visit to the Company’s web site at www.ceapro.com.

Ahead-seeking info

The info in this news release has been well prepared as at February 22, 2024. Sure statements produced herein, which includes statements relating to issues that are not historical info and statements of the Company’s beliefs, intentions and anticipations about developments, benefits and functions which will or might come about in the long term, represent “forward-hunting information” inside the indicating of applicable Canadian securities laws. Forward-seeking facts relates to long term activities or long run general performance, mirror existing anticipations or beliefs regarding long term gatherings and is usually identified by words this sort of as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “expect”, “forecast”, “future”, “intend”, “maintain”, “may”, “outlook”, “plan”, “potential”, “project”, “synergies”, “will”, and identical expressions suggesting upcoming results or statements with regards to an outlook. Ahead-searching details involves, but is not confined to, statements with regard to the Arrangement, like the expected timing and consequence of the Assembly, closing and many other methods to be done in relationship with the Arrangement, and other statements that are not historic info, including the Company’s skill to get regulatory approvals, such as all those from health and fitness authorities, and to acquire, introduce, and apply new products and solutions as well as enhancements for existing goods that fulfill customer requires and item prerequisites in a timely fashion.

Forward-searching data is dependent on selected assumptions and other essential aspects that, if untrue, could lead to the true results, general performance or achievements of the Firm or the merged organization to be materially different from long run final results, overall performance or achievements expressed or implied by this sort of information and facts. There can be no assurance that such information and facts will confirm to be correct. These info is based mostly on many assumptions, such as assumptions relating to the ability to finish the Arrangement on the contemplated terms or at all that the situations precedent to closing of the Arrangement can be content, which includes the timely receipt of all essential court docket, regulatory, 3rd-get together and Securityholder approvals current and future small business approaches functions functionality within envisioned ranges market place and marketplace anticipations thriving and well timed item launches and the skill to defend the Company’s mental house.

Audience are cautioned not to position undue reliance on ahead-seeking information, which talk only as of the date built. For a additional in depth dialogue of these kinds of threats and other aspects that could influence Ceapro’s ability to attain the expectations set forth in the forward-searching details contained in this news release, see Ceapro’s administration information and facts circular dated February 9, 2024, MD&A filed underneath Ceapro’s profile on SEDAR+ at www.sedarplus.ca, as very well as Ceapro’s other filings with the Canadian securities regulators. Other than as needed by law, the Organization does not intend, and does not assume any obligation to, update the forward-looking details in this information release.

For far more details call: 
Jenene Thomas 
JTC Workforce, LLC 
Trader Relations and Corporate Communications Advisor 
T (US): +1 (833) 475-8247 
E: czo@jtcir.com

Issuer:
Gilles R. Gagnon, M.Sc., MBA
President & CEO
T: 780-421-4555

Neither the TSX Enterprise Exchange nor its Regulation Services Service provider (as that phrase is outlined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release